Study guide

7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

Certified Burn Registered Nurse CBRN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Foundations of Burn Care

1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones

2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response

2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria

3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics

4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)

4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy

5 Chapter 5: Airway Management & Inhalation Injury Management

5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)

6 Chapter 6: Acute Multisystem Assessment & Critical Care Management

6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection

7 Chapter 7: Hypermetabolism & Nutritional Support

7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

8 Chapter 8: Pain Management in Burn Care

8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction

9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings

10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances

11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure

11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management

12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy

12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion

13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries

13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy

14 Chapter 14: Special Burn Populations & Cutaneous Syndromes

14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries

15 Chapter 15: Rehabilitation, Scar Management & Reconstruction

15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management

16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage

16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response

7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

Key Takeaways Explain This Topic AI

Post-burn stress-induced hyperglycemia is driven by excessive hepatic gluconeogenesis/glycogenolysis and severe peripheral insulin resistance mediated by post-receptor GLUT4 signaling defects and pro-inflammatory cytokines.

Uncontrolled hyperglycemia (>180 mg/dL) causes neutrophil phagocytic dysfunction, increased burn wound infection and sepsis, osmotic diuresis (which falsely elevates urine output and leads to dangerous under-resuscitation), graft failure, and increased mortality.

The American Burn Association (ABA) recommends a target blood glucose corridor of 130 to 180 mg/dL (7.2 to 10.0 mmol/L); ultra-tight glycemic control (<110 mg/dL) is strictly avoided due to the life-threatening risks of severe hypoglycemia.

Continuous intravenous regular insulin infusion is the standard of care during the acute and hypermetabolic phases; subcutaneous insulin is unreliable due to massive extremity edema and altered tissue perfusion.

Endocrine axis alterations in severe burns include Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in refractory septic shock (treated with stress-dose hydrocortisone) and Euthyroid Sick Syndrome (low T3, low/normal T4, normal TSH), which represents an adaptive hypometabolic response that should not be treated with exogenous thyroid hormones.

Last updated: August 2026

7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

Core Knowledge: Severe thermal trauma profoundly disrupts systemic endocrine homeostasis, precipitating severe stress-induced hyperglycemia , peripheral insulin resistance, adrenal axis exhaustion, and altered thyroid hormone metabolism. Even in patients without pre-existing diabetes, circulating glucose levels frequently surge above 250 to 300 mg/dL 250\text{ to }300\text{ mg/dL} 250 to 300 mg/dL . Uncontrolled hyperglycemia suppresses immune defense, degrades newly grafted tissue, and triggers osmotic diuresis —a deceptive phenomenon that can mislead fluid resuscitation. Certified Burn Registered Nurses (CBRN) must master protocolized continuous intravenous insulin therapy, recognize endocrine failure states such as CIRCI , and avoid unnecessary hormonal interventions in Euthyroid Sick Syndrome .

1. Pathophysiology of Burn-Induced Stress Hyperglycemia

Stress hyperglycemia in severe burns is not simply a relative insulin deficiency; it is a complex metabolic derangement characterized by accelerated endogenous glucose output combined with massive peripheral insulin resistance. DUAL PATHWAY OF POST-BURN STRESS HYPERGLYCEMIA

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Thermal Injury (≥20–40% TBSA) & Systemic SIRS │
  • └──────────────────────────────────────┬──────────────────────────────────────┘
  • │
  • ┌───────────────────────────────┴───────────────────────────────┐
  • ▼ ▼
  • ┌──────────────────────────────┐ ┌──────────────────────────────┐
  • │ UNCHECKED HEPATIC GLUCOSE │ │ PERIPHERAL SKELETAL │
  • │ PRODUCTION │ │ INSULIN RESISTANCE │
  • ├──────────────────────────────┤ ├──────────────────────────────┤
  • │ • Catecholamines & Cortisol │ │ • TNF-α, IL-6 & circulating │
  • │ drive glycogenolysis │ │ FFAs induce serine │
  • │ • Glucagon stimulates │ │ phosphorylation of IRS-1 │
  • │ gluconeogenesis │ │ • Impaired intracellular │
  • │ • Liver remains refractory to│ │ translocation of GLUT4 │
  • │ normal insulin feedback │ │ vesicles to cell membrane │
  • │ suppression │ │ • Skeletal muscle cannot │
  • │ │ │ import circulating glucose │
  • └──────────────┬───────────────┘ └──────────────┬───────────────┘
  • │ │
  • └───────────────────────────────┬─────────────────────────────┘
  • │
  • ▼
  • ┌──────────────────────────────┐
  • │ SEVERE HYPERGLYCEMIA │
  • │ (Blood Glucose >180–300) │
  • └──────────────────────────────┘

Molecular Mechanisms:

Hepatic Gluconeogenesis Surge: The liver increases glucose production up to 200% to 300% of normal , driven by the continuous supply of gluconeogenic precursors (alanine, glutamine, lactate, and glycerol) and high glucagon-to-insulin ratios.

Post-Receptor GLUT4 Defect: Circulating pro-inflammatory cytokines (especially TNF- α \alpha α and IL-6) and high levels of intracellular free fatty acids phosphorylate the Insulin Receptor Substrate-1 (IRS-1) on serine residues rather than tyrosine residues. This halts downstream PI3K/Akt signaling, preventing the translocation of Glucose Transporter 4 (GLUT4) vesicles to the sarcolemma in skeletal muscle.

  • 2. Clinical Consequences of Glucose Toxicity in Burns
  • Maintaining glycemic control is essential to prevent systemic failure: HAZARDS OF UNCONTROLLED HYPERGLYCEMIA
  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ 1. IMMUNE DEFENSE IMPAIRMENT: │
  • │ • Inhibits neutrophil chemotaxis, phagocytosis, and oxidative burst. │
  • │ • Increases incidence of bacteremia, pneumonia, and invasive wound sepsis│
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 2. OSMOTIC DIURESIS & RESUSCITATION DECEPTION: │
  • │ • Blood glucose >180 mg/dL exceeds renal tubular reabsorption capacity. │
  • │ • Glycosuria pulls water into urine, falsely elevating hourly urine │
  • │ output (UOP) despite ongoing severe intravascular hypovolemia! │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 3. GRAFT FAILURE & POOR WOUND REPAIR: │
  • │ • Endothelial dysfunction and non-enzymatic glycation of tissue proteins.│
  • │ • Impairs fibroblast proliferation and halts split-thickness graft take. │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 4. ACCELERATED MUSCLE CATABOLISM & MORTALITY: │
  • │ • Induces mitochondrial dysfunction, increases apoptosis, and worsens │
  • │ hyperosmolar stress and multi-organ failure. │
  • └─────────────────────────────────────────────────────────────────────────────┘

[!CRITICAL] Resuscitation Deception Alert: When a burn patient's blood glucose exceeds ≈ 180 mg/dL \approx 180\text{ mg/dL} ≈ 180 mg/dL , glucose spills into the renal tubules, producing an osmotic diuresis . An inexperienced clinician seeing a urine output of 1.5 mL/kg/hr 1.5\text{ mL/kg/hr} 1.5 mL/kg/hr might inappropriately decrease fluid resuscitation rates. In reality, the patient is losing volume to osmotic diuresis while their intravascular compartment remains severely hypoperfused. Always check urine for glucose and verify blood glucose levels when interpreting urine output!

  • 3. Glycemic Targets and Continuous IV Insulin Protocols
  • Evolution of Evidence-Based Glycemic Targets

Historical Tight Control (80–110 mg/dL): Popularized by early single-center trials, this approach was conclusively refuted by the multicenter NICE-SUGAR trial , which demonstrated that ultra-tight control resulted in unacceptable rates of fatal hypoglycemia and increased mortality.

American Burn Association (ABA) Target Corridor: 130 to 180 mg/dL (7.2 to 10.0 mmol/L) .

This range captures the anabolic, anti-inflammatory, and wound-healing benefits of insulin therapy while providing a safe buffer against clinical hypoglycemia. GLYCEMIC CONTROL TARGET CORRIDORS

  • Blood Glucose (mg/dL)
  • 300 ┼────────────────────────────────────────────────────────── Severely Elevated
  • 250 ┼
  • 200 ┼
  • 180 ┼────────────────────────────────────────────────────────── Upper Target Limit
  • │ OPTIMAL ABA TARGET CORRIDOR (130–180 mg/dL)
  • 130 ┼────────────────────────────────────────────────────────── Lower Target Limit
  • 110 ┼
  • 70 ┼────────────────────────────────────────────────────────── Hypoglycemia Threshold
  • 40 ┼────────────────────────────────────────────────────────── Severe / Neuroglycopenia
  • Continuous IV Regular Insulin Infusion Principles

Route of Administration: Continuous IV infusion is mandatory . Subcutaneous injections (e.g., glargine, lispro) are contraindicated in acute burns due to erratic, unpredictable absorption across edematous subcutaneous tissues.

Dynamic Protocol Titration: Regular insulin is infused via a dedicated IV line, titrated hourly based on point-of-care (POC) blood glucose or arterial line blood gas measurements.

Anabolic Action of Insulin: Beyond glucose lowering, exogenous insulin acts as an anabolic hormone in burns—stimulating skeletal muscle amino acid uptake, suppressing proteolysis, and promoting hepatic protein synthesis.

Nursing Management of Hypoglycemia

Threshold: Blood glucose < 70 mg/dL <70\text{ mg/dL} < 70 mg/dL (severe < 40 mg/dL <40\text{ mg/dL} < 40 mg/dL ).

Immediate Protocol Action:

Stop the continuous IV regular insulin infusion immediately.

Administer 25 to 50 mL of 50% Dextrose (D50W) IV push (12.5 to 25 g dextrose).

Recheck blood glucose every 15 minutes until blood glucose is ≥ 100 mg/dL \ge 100\text{ mg/dL} ≥ 100 mg/dL .

The Enteral Feed Rule: If enteral nutrition or TPN is paused for any reason (e.g., extubation, bedside wound debridement, or operating room transport), the nurse must immediately decrease the insulin infusion rate or start a concurrent infusion of 10% Dextrose in Water (D10W) at the same hourly rate to prevent sudden, catastrophic hypoglycemia.

4. Endocrine Axis Alterations in Major Thermal Injury

Severe burns induce dramatic secondary disturbances across the adrenal and thyroid axes that require discerning clinical management. ENDOCRINE AXIS DISTURBANCES IN SEVERE BURNS

  • ┌────────────────────────────────────────┬────────────────────────────────────────┐
  • │ ADRENAL AXIS DYSFUNCTION │ THYROID AXIS DYSFUNCTION │
  • │ (CIRCI) │ (Euthyroid Sick Syndrome) │
  • ├────────────────────────────────────────┼────────────────────────────────────────┤
  • │ • Initial Stage: Extreme high cortisol │ • Hormone Profile: Low T3, low/normal │
  • │ • Late Stage: Adrenal exhaustion and │ T4, normal/low TSH, high reverse T3 │
  • │ tissue corticosteroid resistance │ • Mechanism: Downregulation of │
  • │ • Clinical Sign: Vasopressor-refractory│ peripheral 5'-deiodinase by cytokines│
  • │ hypotension in septic shock │ • Clinical Meaning: Evolutionary │
  • │ • Diagnosis: Random total cortisol │ adaptive hypometabolism to save LBM │
  • │ <10 mcg/dL or delta <9 mcg/dL after │ • Treatment: DO NOT ADMINISTER THYROID │
  • │ cosyntropin stimulation │ HORMONE REPLACEMENT; therapy worsens │
  • │ • Treatment: Stress-dose Hydrocortisone│ protein wasting and cardiac strain │
  • │ (200–300 mg/day IV divided/drip) │ │
  • └────────────────────────────────────────┴────────────────────────────────────────┘
  • 1. Critical Illness-Related Corticosteroid Insufficiency (CIRCI)

Following the initial hypercortisolemic surge, prolonged critical illness and endotoxemia can impair adrenal steroidogenesis and downregulate glucocorticoid receptors.

Presentation: Suspected in burn patients with septic shock who remain persistently hypotensive (MAP < 65 mmHg <65\text{ mmHg} < 65 mmHg ) despite aggressive fluid resuscitation and escalating high-dose vasopressor support (norepinephrine > 0.25 mcg/kg/min >0.25\text{ mcg/kg/min} > 0.25 mcg/kg/min plus vasopressin).

Management: Administer stress-dose Hydrocortisone 50 mg IV every 6 hours (or 200 mg/day continuous IV infusion) until shock resolves, followed by a gradual taper.

2. Euthyroid Sick Syndrome (Non-Thyroidal Illness Syndrome)

Burn cytokines (IL-6, TNF- α \alpha α ) and high cortisol inhibit hepatic 5'-deiodinase , blunting the peripheral conversion of thyroxine ( T 4 T_4 T 4 ​ ) into active triiodothyronine ( T 3 T_3 T 3 ​ ), shunting metabolism toward inactive reverse T 3 T_3 T 3 ​ ( r T 3 rT_3 r T 3 ​ ) .

Clinical Rule: This represents a protective, energy-conserving physiologic adaptation. Administering levothyroxine ( T 4 T_4 T 4 ​ ) or liothyronine ( T 3 T_3 T 3 ​ ) is strictly contraindicated because it accelerates skeletal muscle proteolysis, exacerbates hypermetabolism, and increases mortality.